Abstract
Cardiac amyloidosis, once considered untreatable, is now gaining well-deserved attention due to advances in imaging and the recent approval of targeted breakthrough therapies. In this paper, we discuss the role of radionuclide imaging in the evaluation and management of patients with the most common form of amyloidosis-cardiac transthyretin amyloidosis (ATTR). We provide a comprehensive summary of the literature interspersed with our institutional experience as appropriate, to deliver our perspective.
Keywords:
Amyloid heart disease; PET; SPECT; modalities; molecular imaging.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Amyloid Neuropathies, Familial / diagnostic imaging
-
Amyloidosis / diagnostic imaging*
-
Bone and Bones / diagnostic imaging
-
Cardiomyopathies / diagnostic imaging
-
Heart / diagnostic imaging*
-
Humans
-
Prealbumin / metabolism*
-
Radionuclide Imaging
-
Technetium Tc 99m Medronate
-
Technetium Tc 99m Pyrophosphate
-
Tomography, Emission-Computed, Single-Photon
Substances
-
Prealbumin
-
Technetium Tc 99m Pyrophosphate
-
Technetium Tc 99m Medronate
Supplementary concepts
-
Amyloidosis, Hereditary, Transthyretin-Related